Purpose

This study assesses the effect of hormone directed treatment for breast cancer on glucose metabolism.

Condition

Eligibility

Eligible Ages
All ages
Eligible Sex
Female
Accepts Healthy Volunteers
Yes

Inclusion Criteria

  • Post-menopausal women with hormone receptor positive breast cancer, ductal carcinoma in situ (DCIS), or with other high risk breast conditions. Post-menopause will be defined as women who experience 12 months of amenorrhea or have undergone bilateral salpingo-oophorectomy. - 25 women who are planning to start or are within 6 months of starting treatment with aromatase inhibitors, after consultation in breast clinic and cancer center. - 25 women who will be starting Tamoxifen (comparative group) - 25 healthy post menopausal women will also be recruited.

Exclusion Criteria

  • Established diagnosis of diabetes - Therapy with medications that could affect glucose metabolism - Screening fasting glucose ≥ 126 mg/dl, and/or HbA1c ≥ 6.5% - History of upper GI surgery that alters gastric emptying or causing malabsorption e.g., bariatric surgery, fundoplication

Study Design

Phase
Study Type
Observational
Observational Model
Cohort
Time Perspective
Prospective

Arm Groups

ArmDescriptionAssigned Intervention
Observational Patients undergo blood sample collection, glucose testing, DEXA scan to measure body composition, complete a questionnaire and have their medical records reviewed on study.
  • Other: Non-Interventional Study
    Non-Interventional Study

Recruiting Locations

Mayo Clinic in Rochester
Rochester, Minnesota 55905
Contact:
Clinical Trials Referral Office
855-776-0015
mayocliniccancerstudies@mayo.edu

More Details

Status
Recruiting
Sponsor
Mayo Clinic

Study Contact

Clinical Trials Referral Office
855-776-0015
mayocliniccancerstudies@mayo.edu

Detailed Description

PRIMARY OBJECTIVE: I. Assess the impact of endocrine adjuvant therapy with aromatase inhibitors in women with hormone receptor positive breast cancer, ductal carcinoma in situ (cancer, DCIS ), or women with other high risk breast conditions, on various indices of glucose homeostasis, utilizing oral minimal model assessment, in comparison to healthy post menopausal women and another cohort of women on tamoxifen. OUTLINE: This is an observational study. Patients undergo blood sample collection, glucose testing, dual-energy x-ray absorptiometry (DEXA) scan to measure body composition, complete a questionnaire and have their medical records reviewed on study.

Notice

Study information shown on this site is derived from ClinicalTrials.gov (a public registry operated by the National Institutes of Health). The listing of studies provided is not certain to be all studies for which you might be eligible. Furthermore, study eligibility requirements can be difficult to understand and may change over time, so it is wise to speak with your medical care provider and individual research study teams when making decisions related to participation.